aTyr Pharma Inc.

(LIFE) Trade

By |

Profile

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

Contact Information

Website: www.atyrpharma.com
Email: investorrelations@atyrpharma.com
Main Phone: +1 858 731-8389
Address: 3545 John Hopkins Court
Address 2: Suite 250
State: CA
City / Town: San Diego
Country: US
Postal Code: 92121

Issuer Information

Exchange: NSC
CEO: Sanjay S. Shukla
Employees: 44
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More

Profile

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

Contact Information

Website: www.atyrpharma.com
Email: investorrelations@atyrpharma.com
Main Phone: +1 858 731-8389
Address: 3545 John Hopkins Court
Address 2: Suite 250
State: CA
City / Town: San Diego
Country: US
Postal Code: 92121

Issuer Information

Exchange: NSC
CEO: Sanjay S. Shukla
Employees: 44
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
$ 3.26 $ -0.05 (-1.51%)
Last Price 3.26 Change $ -0.05 Change % -1.51 Tick N/A
Bid 3.02 Bid Size 1,000.00 Ask 3.35 Ask Size 500.00
Open 3.43 High 3.45 Low 3.14 Prev Close 3.31
Last Trade Volume 94,682 52 Wk Hi 7.62 52 Wk Low 2.14
Market Cap 32.6 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 10,007,792.00 EPS (TTM) -3.39 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 2 10
Number of Buys 2 8
Number of Sells 0 2
Net Activity 153333 338796
Last 10 Buys Shares
Paul R. Schimmel 1,000
Paul R. Schimmel 1,000
Paul R. Schimmel 1,000
John D. Mendlein 1,000
John D. Mendlein 1,000
John D. Mendlein 1,000
John D. Mendlein 1,000
John D. Mendlein 1,000
Paul R. Schimmel 1,000
Amanullah Ashraf 1,000
Last 10 Sell Shares
John T. Blake 1,000
Amanullah Ashraf 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 3 3 3 3
Low Target Price Estimate 3 3 3 3
Mean Target Price Estimate 3 3 3 3
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 05/22/18 05/22/18 05/22/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 2 2 1 1
Mean Rec. 3.5 3.5 3 3